نتائج البحث

Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD) (PRImus-AD)

• Authors : Priavoid; Federal Agency for Disruptive Innovation - SPRIN-D; Julius Clinical

• Source: Randomised, Double-blind, Placebo-controlled Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's

تفاصيل العنوان

Study of the Indications for Amyloid Positon Emission Tomography (PET) Scans and Their Usefulness for Patients With Suspected Alzheimer's Disease (AD) (TEPAmy)

• Authors : Antoine VERGER, Investigator coordinator

• Source: Study of the Indications for Amyloid PET Scans and Their Usefulness in the Management of Patients With Suspected Alzheimer's Disease

تفاصيل العنوان

A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)

• Source: A Patient- and Investigator-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Study Participants With Prodromal to Mild

تفاصيل العنوان

A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)

• Source: A Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, PK and PD of LY4006895 in Healthy Volunteers and Patients With Early Symptomatic

تفاصيل العنوان

A Study of LY3372993 in Participants With Alzheimer's Disease (AD) and Healthy Participants

• Source: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3372993 in Participants With Alzheimer's Disease

تفاصيل العنوان

Behavioral Change Following Alzheimer's Disease (AD) Biomarker Disclosure (SHARED III)

• Authors : National Institute on Aging (NIA); Annalise Rahman-Filipiak, Assistant Professor of Psychiatry

• Source: Behavioral Change Following Culturally Informed Biomarker Disclosure in Alzheimer's Disease

تفاصيل العنوان

A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)

• Source: A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Multicenter, Parallel-Group Study to Investigate the Safety, Tolerability, and the Effect of RO7269162 on Amyloid and

تفاصيل العنوان

A First in Human Study of IBC-Ab002 in Persons With Early Alzheimer's Disease (AD)

• Authors : National Institute on Aging (NIA); Alzheimer's Association

• Source: A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IBC-Ab002 in Persons With Early Alzheimer's Disease

تفاصيل العنوان

Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer's Disease (AD)

• Source: A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacokinetics of ION269 in Adults With Down Syndrome (Hero Study)

تفاصيل العنوان

A Study of Silkworm Pupa Powder Intervention in the Nutritional Status of Patients with Alzheimer's Disease. (AD)

• Authors : Yanbu Ke, The director of Hangzhou First People's Hospital(Hangzhou Geriatric Hospital)

• Source: A Prospective, Double-blind, Randomized Controlled Clinical Study of Silkworm Pupa Powder Intervention in the Nutritional Status of Patients with Alzheimer's

تفاصيل العنوان